A comparison of specificity and biological activity of polyclonal and monoclonal antibodies raised against Salmonella minnesota R595 lipopolysaccharide

References

1. Appelmelk B J, Verweij-Van-Vught A M J J, Maclaren D M, Thiys L G. 1985; An enzyme-linked immunosorbent assay (ELISA) for the measurement of antibodies to different parts of the gram-negative lipopolysaccharide core region. Journal of Immunological Methods 82:199–207
   [Google Scholar]
2. Appelmelk B J. 1988; Production and characterisation of mouse monoclonal antibodies reacting with the lipopolysaccharide core region of gram-negative bacilli. Journal of Medical Microbiology 26:107–114
   [Google Scholar]
3. Baumgartner J D et al. 1985; Prevention of gram-negative shock and death in surgical patients by antibody to endotoxin core glycolipid. Lancet 2:59–63
   [Google Scholar]
4. Bogard W C, Abernethy K, Dunn D L, Kung P C. 1984; Murine monoclonal antibodies against gram-negative bacterial core-glycolipid : criteria for cross-genera reactivity. Federation Proceedings 43:1682 abstract no. 1553.
   [Google Scholar]
5. Braude A I, Ziegler E J, Douglas H, McCutchan J A. 1977; Antibody to cell wall glycolipid of gram-negative bacteria: induction of immunity to bacteremia and endotoxemia. Journal of Infectious Diseases 136:S167–S173
   [Google Scholar]
6. Crowley J P, Zinner S H, Peter G. 1982; Opsonization of serumsensitive and serum-resistant Escherichia coli by rough mutant (Re) antisera. Journal of Laboratory and Clinical Medicine 99:197–205
   [Google Scholar]
7. Dunn D L, Mach P A, Cerra F B. 1983; Monoclonal antibodies protect against lethal effects of gram-negative bacterial sepsis. Surgical Forum 44:142–143
   [Google Scholar]
8. Dunn D L, Bogard W C, Cerra F B. 1985; Enhanced survival during murine gram-negative bacterial sepsis by use of a murine monoclonal antibody. Archives of Surgery 120:50–53
   [Google Scholar]
9. Dunn D L, Ewald D C, Chandan N, Cerra F B. 1986; Immunotherapy of gram-negative bacterial sepsis. A single murine monoclonal antibody provides cross-genera protection. Archives of Surgery 121:58–62
   [Google Scholar]
10. Eisenstein T K. 1975; Evidence of O-antigens as the antigenic determinants in “ribosomal” vaccines prepared from Salmonella. Infection and Immunity 12:364–377
    [Google Scholar]
11. Galanos C, Luderitz O, Westphal O. 1969; A new method for the extraction of R-lipopolysaccharides. European Journal of Biochemistry 9:245–249
    [Google Scholar]
12. Galanos C, Luderitz O, Westphal O. 1971; Preparation and properties of antisera against the lipid-A component of bacterial lipopolysaccharides. European Journal Biochemistry 24:116–122
    [Google Scholar]
13. Galanos C, Freudenberg M, Hase S, Jay F, Ruschmann E. 1977; Biological activitiesimmunological properties of lipid. Schlessinger D A. Microbiology American Society of Microbiology Washington, DC:269–276
    [Google Scholar]
14. Galfre G, Milstein- C. 1982; Chemical typing of human kappa light chain subgroups expressed by human hybrid myelomas. Immunology 45:125–128
    [Google Scholar]
15. Greisman S E, Dubuy J B, Woodward C L. 1978; Experimental gram-negative bacterial sepsis : re-evaluation of the ability of rough mutant antisera to protect mice. Proceedings of the Society for Experimental Biology and Medicine 158:482–490
    [Google Scholar]
16. Ivanyi J, Davies P. 1980; Monoclonal antibodies against human growth hormone. Molecular Immunology 17:287–290
    [Google Scholar]
17. Johns M, Skehill A, McCabe W R. 1983; Immunization with rough mutants of Salmonella minnesota. IV. Protection by antisera to 0 and rough antigens against endotoxin. Journal of Infectious Diseases 147:57–67
    [Google Scholar]
18. Kohler G, Milstein C. 1976; Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256:495–497
    [Google Scholar]
19. Kreger B E, Craven D E, Carling P C, McCabe W R. 1980; Gram-negative bacteremia. 111. Reassessment of etiology, epidemiology and ecology in 61 2 patients. American Journal of Medicine 68:332–343
    [Google Scholar]
20. McCabe W R. 1972; Immunization with R mutants of S minnesota. I. Protection against challenge with heterologous gram-negative bacilli. Journalof Immunology 108:601–610
    [Google Scholar]
21. Mehta N D, Wilson B M, Rapson N T, Easmon C S F. 1988; Comparison of the opsonic activity of polyclonal and monoclonal antibodies raised against Salmonella minnesota R595. Journal of Medical Microbiology 25:85–93
    [Google Scholar]
22. Milner K C, Finkelstein R A. 1966; Bioassay of endotoxin: correlation between pyrogenicity for rabbits and lethality for chick embryos. Journal of Infectious Diseases 116:529–536
    [Google Scholar]
23. Morrison D C, Ulevitch R J. 1978; The effects of bacterial endotoxins on host mediation systems. A review. American Journal of Pathology 93:526–617
    [Google Scholar]
24. Ng A K, Chen C L H, Chang C M, Nowotny A. 1976; Relationship of structure to function in bacterial endotoxins : serologically cross-reactive components and their effect on protection of mice against some gram-negative infections. Journalof General Microbiology 94:107–116
    [Google Scholar]
25. Pennington J E, Menkes E. 1981; Type-specific vs. crossprotective vaccination for gram-negative bacterial pneumonia. Journal of Infectious Diseases 144:599–603
    [Google Scholar]
26. Pollack M, Raubitschek A A, Larrick J W. 1987; Human monoclonal antibodies that recognize conserved epitopes in the core-lipid A region of lipopolysaccharides. Journal of Clinical Investigation 79:1421–1430
    [Google Scholar]
27. Ramachandra R N, Berczi I, Sehon A H. 1988; Human-human hybridomas secreting lipid A monoclonal antibodies. Immunology Letters 18:93–98
    [Google Scholar]
28. Raubitschek A A, Pollack M, Larrick J W. 1985; Preparation of human monoclonal antibodies (mAbs) that react with the conserved core region of endotoxin (LPS). Clinical Research 33:416A
    [Google Scholar]
29. Rietschel E T, Sidorczyk L, Zahringer U, Wollenweber H-W, Luderitz O. 1983; Analysis of the primary structure of lipid A. Anderson L, Unger F M. Bacterial lipopolysaccharides. Structure, synthesis, biological activities American Chemical Symposium Series 231 American Chemical Society; Washington, DC:195–218
    [Google Scholar]
30. Svenson S B, Nurminen M, Lindberg A A. 1979 Artificial salmonella vaccines: O-antigenic oligosaccharide-protein conjugates induce protection against infection with Salmonella typhimurium. Infection and Immunity 25:863–872
    [Google Scholar]
31. Taylor R L, Conrad H E. 1972; Stoichiometric depolymerization of polyuronides and glucosaminoglycuronans to monosaccharides following reduction to their carbodiimide-activated carboxyl groups. Biochemistry 11:1383–1388
    [Google Scholar]
32. Telzak E E, Wolff S M. 1985; Immunotherapy and immunoprophylaxis of gram-negative rod bacteremia. Root R K, Sande M A. Septic shock Churchill Livingstone; New York:257–276
    [Google Scholar]
33. Teng N N H et al. 1985; Protection against gram-negative bacteremia and endotoxemia with human monoclonal IgM antibodies. Proceedings of the National Academy of Sciences of the USA 82:1790–1794
    [Google Scholar]
34. Van Dijk W C, Verbrugh H A, Van Erne-Van Der To1 M E, Peters R, Verhoef J. 1981; Escherichia coli antibodies in opsonisation and protection against infection. Journal of Medical Microbiology 14:381–389
    [Google Scholar]
35. Westphal O, Jann K. 1965; Bacterial lipopolysaccharides. Extraction with phenol water and further applications of the procedure. Methods in carbohydrate chemistry 5:83–91
    [Google Scholar]
36. Wolff S M. 1982; The treatment of gram-negative bacteremia and shock (editorial). New England Journal of Medicine 307:1267–1268
    [Google Scholar]
37. Ziegler E J, Douglas H, Sherman J E, Davis C E, Braude A I. 1973; Treatment of E. coli and Klebsiella bacteremia in agranulocytic animals with antiserum to a UDP-Gal epimerase-deficient mutant. Journal of Immunology 111:433–438
    [Google Scholar]
38. Ziegler E J et al. 1982; Treatment of gram-negative bacteraemia and shock with human antiserum to a mutant Escherichia coli. New England Journal of Medicine 307:1225–1230
    [Google Scholar]
39. Zinner S H, Peter G. 1983; The potential role of cell wall core glycolipids in the immunoprophylaxis and therapy of gramnegative rod bacteraemia. Easmon C S F, Jeljaszewicz J. Medical microbiology 11: Academic Press; London:71–851267–1268
    [Google Scholar]